Sign in to continue:

Friday, March 6th, 2026

Overseas Chinese Town (Asia) Issues Profit Warning for 2025, Expects Significant Increase in Losses




Overseas Chinese Town (Asia) Holdings Limited – Detailed Profit Warning Report

Overseas Chinese Town (Asia) Holdings Limited Issues Significant Profit Warning for 2025

Key Highlights

  • Expected Loss: The company anticipates a substantial loss attributable to equity holders for the year ending 31 December 2025. The projected loss is not exceeding RMB1,800 million, a dramatic increase compared to RMB170 million in 2024.
  • Absence of One-off Investment Income: In 2024, the company recorded a one-off investment income from the disposal of equity interests in a comprehensive development project. This event will not recur in 2025, removing a significant positive impact from the previous year’s results.
  • Provision for Impairment: For 2025, the company has made provisions for impairment losses on inventories and construction in progress for certain comprehensive development projects. Additionally, recognised investment losses and impairment losses on investments in certain associates and joint ventures have been recorded.

Details for Investors and Shareholders

  • Liquidity and Resource Allocation: The company is making these provisions to enhance liquidity, optimize resource allocation, and adjust operational and sales strategies in response to changing market conditions.
  • Impact on Cash Flow: The board believes that these impairment provisions and investment losses will not have a material impact on the group’s cash flow, signaling that operational liquidity is being maintained despite the large accounting losses.
  • Strategic Focus for 2026: The company will continue to prioritize “destocking inventory, revitalizing assets, and mitigating risks,” accelerating the sale of existing projects and fund recovery. Other strategic actions include strengthening cash flow control, promoting cost reduction and efficiency enhancement, improving risk prevention and control, and enhancing operational efficiency to create shareholder value.
  • Financial Report Status: The 2025 financial report is still being finalized. The information in this profit warning is based on preliminary assessments and unaudited management accounts, which may be subject to change upon audit review.
  • Next Steps: The company plans to release its annual results announcement in March 2026, which will provide further details and confirmation of the 2025 financial results.

Price Sensitive Information

  • The scale of the expected loss (up to RMB1,800 million) is significantly larger than the previous year and is likely to be considered highly price sensitive for investors and shareholders.
  • The absence of one-off gains and the recognition of impairment losses could substantially impact investor sentiment and the company’s valuation.
  • Shareholders and potential investors are specifically cautioned to exercise care when dealing in the company’s securities, given the uncertainty and the possibility of further changes to the financial results.

Board Composition

  • The board currently consists of seven directors: three executive directors (Ms. Liu Yu, Mr. Wang Jianwen, Ms. Qi Jianrong), one non-executive director (Mr. Yang Guobin), and three independent non-executive directors (Ms. Wong Wai Ling, Mr. Lam Sing Kwong Simon, Mr. Chu Wing Yiu).

Disclaimer

Disclaimer: The information presented in this article is based on unaudited preliminary management accounts and estimates provided by Overseas Chinese Town (Asia) Holdings Limited. Actual results may differ materially from these projections. Investors are advised to review the company’s official audited financial statements when available and exercise caution in any investment decision. This article is for informational purposes only and does not constitute investment advice.




View OCT (ASIA) Historical chart here



Shanghai Junshi Biosciences Announces 2025 Preliminary Results: Revenue Growth and Narrowed Net Losses Driven by Toripalimab Sales Expansion 1

Shanghai Junshi Biosciences 2025 Preliminary Results: Key Highlights for Investors Shanghai Junshi Biosciences Announces 2025 Preliminary Results: Strong Revenue Growth and Narrowing Losses Shanghai Junshi Biosciences Co., Ltd. (Stock code: 1877) has released its...

Disclosure of Share Dealings in ENN Energy Holdings Limited by Morgan Stanley & Co. International plc – February 2026

Key Disclosure: Morgan Stanley Dealings in ENN Energy Holdings Limited Shares Morgan Stanley Discloses Significant Dealings in ENN Energy Holdings Shares Amid Privatisation Scheme Date: 23 February 2026 Subject: Disclosure of Dealings in ENN...

COSCO SHIPPING Ports Limited Announces Board Meeting to Approve 2025 Annual Results and Dividend Consideration on 18 March 2026 1

COSCO SHIPPING Ports Limited Announces Board Meeting to Approve Annual Results and Consider Dividend COSCO SHIPPING Ports Limited Schedules Board Meeting to Approve 2025 Annual Results and Consider Dividend Hong Kong, 4 March 2026...

   Ad